39 results about "Subjective tinnitus" patented technology

A method and device for tinnitus therapy. The method includes generating pure sounds, each having a predetermined frequency, within an audible range, and waiting for a user to press an input button when the user hears the pure sound. Then, the hearing characteristics of the user are interpreted in conjunction with equal loudness contours. From this interpretation, either a tinnitus masking method or a tinnitus retraining therapy are selected according to the hearing characteristics of the user.

The invention relates to methods for the prevention and / or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and / or formulations for local administration to the inner ear. The tinnitus to be prevented and / or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.

A system 2 and method 64 for neurological rehabilitation or training is disclosed. The system 2 can be used to improve listening, comprehension, and communication. The system 2 can be controlled automatically by a remote device 6 or manually by a physician's device 4. The system 2 can store data in, and retrieve data from a database 10 for analysis, reporting and execution. The system 2 can adapt and adjust based on the subject's performance. The system 2 can be used to treat hearing loss, tinnitus or other audiological health problems.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful NI for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein, , R1, R2, R3a, R3b, R4a, and R4b are as defined herein, and A is a carbon bound substituted or unsubstituted 5-to6-membered heteroaryl ring as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Compositions, and methods of use thereof, are provided for the prevention, treatment or alleviation of symptoms of hearing are provided. Embodiments of the methods employ zonisamide as the sole active pharmaceutical agent or a combination of zonisamide and another pharmaceutical agent, such as an antioxidant, a NMDA antagonist, an SSRI or a combined SSRI / NMDA antagonist agent. Other embodiments of the method involve the use of zonisamide alone or in combination with another API to prevent, treat or ameliorate one or more symptoms of hearing loss. Hearing disorders treatable with the invention include noise-induced hearing loss, drug-induced hearing loss, central auditory hearing disorder (CAPD), tinnitus and presbyacusis.

An implantable tissue-stimulating device comprising an elongate electrode carrier member (11) having a plurality of electrodes thereon. The electrodes are preferably disposed in a linear array on the carrier member (11) and are adapted to apply a preselected tissue stimulation to the cochlea. The carrier member (11) is preformed from a resiliently flexible biocompatible silicone and extends from a distal end (12) to a stop member (13). The carrier member (11) is adapted for intracochlear but extraluminar insertion within the cochlea of an implantee. In particular, the carrier member (11) is adapted to be implanted in the crevice (21) between the spiral ligament (22) and the endosteum (23) of the lateral wall of the cochlea (20). This is a quite different location to the normal placement of the cochlear implant electrode array in the scala tympani (24) of the cochlea (20). The placement of the carrier member (11) is designed to avoid any breach of the internal ducts of the cochlea (20), such as the scala tympani (24) and scala vestibuli (25) so that the normal hydrodynamic behaviour of the cochlea (20) is not affected by any intrusive device. By preservng the normal hydrodynamic behaviour of the cochlea (20), use of the carrier member (11) maximises the possibility of also preserving any hearing of the implantee that is offered by the cochlea (20). Use of the device in a system for masking or treating the symptoms of tinnitus is also described.

Provided is a pillow and method of marking the pillow to mitigate tinnitus. The pillow includes a first and second portions of fill material, an anchor strip assembly and a pillow casing. The anchor strip assembly is disposed between the first and second portions of fill material. The anchor strip assembly includes an anchor strip and a plurality of speakers secured to the anchor strip at a distance from each other. A first and second edge portions the anchor strip extends beyond edges of the first and second portions of fill material. The pillow casing secures the anchor strip assembly disposed between the first and second portions of the fill material inside the pillow casing such that the first and second edge portions of the anchor strip are secured respectively between a first and second seams of the pillow casing.

The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and / or tinnitus.

The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones with at least one substituent on both the 2- and 4-pyridinyl ring having the chemical structure of formula I: The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula I to modulate GABA and GABAA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and / or GABAA receptors.

An implantable tissue-stimulating device comprising an elongate electrode carrier member (11) having a plurality of electrodes thereon. The electrodes are preferably disposed in a linear array on the carrier member (11) and are adapted to apply a preselected tissue stimulation to the cochlea. The carrier member (11) is preformed from a resiliently flexible biocompatible silicone and extends from a distal end (12) to a stop member (13). The carrier member (11) is adapted for intracochlear but extraluminar insertion within the cochlea of an implantee. In particular, the carrier member (11) is adapted to be implanted in the crevice (21) between the spiral ligament (22) and the endosteum (23) of the lateral wall of the cochlea (20). This is a quite different location to the normal placement of the cochlear implant electrode array in the scala tympani (24) of the cochlea (20). The placement of the carrier member (11) is designed to avoid any breach of the internal ducts of the cochlea (20), such as the scala tympani (24) and scala vestibuli (25) so that the normal hydrodynamic behaviour of the cochlea (20) is not affected by any intrusive device. By preservng the normal hydrodynamic behaviour of the cochlea (20), use of the carrier member (11) maximises the possibility of also preserving any hearing of the implantee that is offered by the cochlea (20). Use of the device in a system for masking or treating the symptoms of tinnitus is also described.

A transcutaneous nerve stimulation system includes a multifunctional earphone assembly that receives a sound signal from a sound source or other sources (such as a signal generator). An amplifier receiving the sound signal from the sound source or independent signal generator amplifies the sound signal to generate an amplified electrical signal. A stimulator, which includes multiple conductive electrode contacts, is coupled to the amplifier to receive the amplified electrical signal. The electrode contacts may protrude from an earbud / headphone or extend from an adjustable probe arm. The amplified electrical signal is used to apply electrical stimulation while the earphone assembly emits audible sounds according to the sound signal. The combined functionality enhances compliance with treatment regimens involving electrical stimulation of vagus nerves and other regions of a subject. Potential indications include, without limitation, major depressive disorder, epilepsy, chronic pain, pre-diabetes, insomnia, cardiovascular disorders, tinnitus, autism, daily stress, and anxiety.

The invention discloses a preparation method of a health liquor. The preparation method comprises the following steps: step 1, making base liquor of the health liquor; step 2, making the health liquor by matching the base liquor and medicinal materials; step 3, sealing and storing; and step 4, bottling and packaging. In the processes of liquor brewing, medicinal material soaking and blending, medicinal properties can be completely released into the base liquor after the medicinal materials are soaked into the base liquor and therefore the utilization rate of the medicinal materials is high; the health liquor has outstanding treatment effects on poor sleep, gastrointestinal discomfort, aching lumbus and limp legs, kidney-deficiency impotence, physical and mental fatigue, tinnitus and heart palpitation, has the functions of worming and smoothening blood vessels, strengthening heart and tonifying yang and thus has good health care effect.

The present invention relates to a therapeutic equipment for curing tinnitus due to noise hazard. The connection relationship between all the composition circuits is noise source circuit, it is connected with one end of resistor R2 in amplification circuit by means of capacitor C1, the output end of amplification circuit is connected with one end of resistor R5 is active narrow-band filter, and the output end of the active narrow-band filter is connected with one end of resistor R9 of high pass active filter, and the output end of high pass active filter is connected with input end of power amplification circuit, and the output end of power amplification circuit is connected with earphone.